StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
Shares of NBRV opened at $1.42 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. Nabriva Therapeutics has a 1-year low of $1.22 and a 1-year high of $8.45. The firm has a market cap of $45.46 million, a PE ratio of 0.00 and a beta of 1.53.
Nabriva Therapeutics Company Profile
See Also
- Five stocks we like better than Nabriva Therapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Is Spotify Stock Poised to Soar? Options Traders Think So
- How to Invest in the FAANG Stocks
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Use the MarketBeat Stock Screener
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.